^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Rectal Cancer
    Drug:Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/20/2020
    Excerpt:
    Rectal cancer:.Subsequent therapy...(Trastuzumab + [pertuzumab or lapatinib] or fam-trastuzumab deruxtecan-nxki (HER2-amplified...